1-(3-羟基苯基)-5-氧代-3-吡咯烷羧酸 | 91891-24-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-(3-羟基苯基)-5-氧代-3-吡咯烷羧酸
• 中文别名: 1-(3-羟基苯)-5-氧代吡咯烷-3-羧酸
• 英文名称: 1-(3-hydroxyphenyl)-5-oxo-3-pyrrolidinecarboxylic acid
• 英文别名: 1-(3-hydroxyphenyl)-5-oxopyrrolidine-3-carboxylic acid；N-(3-hydroxyphenyl)-2-oxopyrrolidine-4-carboxylic acid；1-(3-hydroxy-phenyl)-5-oxo-pyrrolidine-3-carboxylic acid；1-(3-Hydroxy-phenyl)-5-oxo-pyrrolidin-3-carbonsaeure
• CAS: 91891-24-6
• 化学式: C₁₁H₁₁NO₄
• mdl: MFCD02197523
• 分子量: 221.213
• InChiKey: SSCXSGYHQKJLBC-UHFFFAOYSA-N

物化性质

• 熔点：
  216-217 °C
• 沸点：
  601.3±50.0 °C(Predicted)
• 密度：
  1.463±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933790090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(3-Hydroxyphenyl)-5-oxopyrrolidine-3-carboxylic acid
Synonyms: 1-(3-Hydroxyphenyl)-2-pyrrolidinone-4-carboxylic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(3-Hydroxyphenyl)-5-oxopyrrolidine-3-carboxylic acid
CAS number: 91891-24-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H11NO4
Molecular weight: 221.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(3-羟基苯基)-5-氧代-3-吡咯烷羧酸 在 sodium carbonate 、 caesium carbonate 、 对甲苯磺酸 、 potassium iodide 作用下， 以 丙酮 为溶剂， 反应 96.0h， 生成 N-[3-[(2-benzthiazolyl)methoxy]phenyl]pyrrolidin-2-on-4-carboxylic acid, methyl ester
  参考文献：
  名称：

  白三烯D4拮抗剂和5-脂氧合酶抑制剂。苯并杂环的[（甲氧基苯基）氨基]氧代链烷酸酯的合成。

  摘要：

  已经制备了一系列新颖的苯并杂环[（甲氧基苯基）氨基]氧代链烷酸酯。这些化合物在体外试验中作为大鼠多形核白细胞5-脂氧合酶（LO）的抑制剂，以及白三烯D4（LTD4）和卵清蛋白（OA）诱导的豚鼠（GP）支气管痉挛的抑制剂。通常，对于含苯并噻唑的类似物（对苯并噻唑大于苯并咪唑比对苯并恶唑，苯并呋喃要大得多）对5-LO，LTD4和OA的抑制活性最广。最有效的5-LO抑制剂4-[[[3-（2-苯并噻唑基甲氧基）-苯基]羟基氨基] -4-氧代丁酸甲酯（7）的IC50为0.36 microM。但是，化合物7与OA相比没有活性。体内最有效的化合物4-[[[3-[（1-甲基-2-苯并咪唑基）甲氧基]苯基]-氨基] -4-氧代丁酸甲酯4，在十二指肠内以50 mg / kg的浓度分别抑制LTD4-和OA诱导的支气管痉挛分别达到83％和60％。在Ames分析中使用五种细菌菌株（TA1535，TA1537，TA1

  DOI：

  10.1021/jm00385a024
• 作为产物：
  描述：

  衣康酸 、 3-氨基苯酚 反应 0.08h， 以97%的产率得到1-(3-羟基苯基)-5-氧代-3-吡咯烷羧酸
  参考文献：
  名称：

  白三烯D4拮抗剂和5-脂氧合酶抑制剂。苯并杂环的[（甲氧基苯基）氨基]氧代链烷酸酯的合成。

  摘要：

  已经制备了一系列新颖的苯并杂环[（甲氧基苯基）氨基]氧代链烷酸酯。这些化合物在体外试验中作为大鼠多形核白细胞5-脂氧合酶（LO）的抑制剂，以及白三烯D4（LTD4）和卵清蛋白（OA）诱导的豚鼠（GP）支气管痉挛的抑制剂。通常，对于含苯并噻唑的类似物（对苯并噻唑大于苯并咪唑比对苯并恶唑，苯并呋喃要大得多）对5-LO，LTD4和OA的抑制活性最广。最有效的5-LO抑制剂4-[[[3-（2-苯并噻唑基甲氧基）-苯基]羟基氨基] -4-氧代丁酸甲酯（7）的IC50为0.36 microM。但是，化合物7与OA相比没有活性。体内最有效的化合物4-[[[3-[（1-甲基-2-苯并咪唑基）甲氧基]苯基]-氨基] -4-氧代丁酸甲酯4，在十二指肠内以50 mg / kg的浓度分别抑制LTD4-和OA诱导的支气管痉挛分别达到83％和60％。在Ames分析中使用五种细菌菌株（TA1535，TA1537，TA1

  DOI：

  10.1021/jm00385a024

文献信息

• Discovery, Synthesis, and Optimization of Diarylisoxazole-3-carboxamides as Potent Inhibitors of the Mitochondrial Permeability Transition Pore
  作者：Sudeshna Roy、Justina Šileikytė、Marco Schiavone、Benjamin Neuenswander、Francesco Argenton、Jeffrey Aubé、Michael P. Hedrick、Thomas D. Y. Chung、Michael A. Forte、Paolo Bernardi、Frank J. Schoenen

  DOI：10.1002/cmdc.201500284

  日期：2015.10

  activity against mitochondrial swelling (EC50<0.39 μM) and showed no interference on the inner mitochondrial membrane potential (rhodamine 123 uptake EC50>100 μM). This enabled the construction of a series of picomolar mtPTP inhibitors that also potently increase the calcium retention capacity of the mitochondria. Finally, the therapeutic potential and in vivo efficacy of one of the most potent analogues

  线粒体通透性转换孔（mtPTP）是一种需要Ca 2+的巨型通道，在病理条件下会导致Ca 2+释放失调和线粒体功能障碍，最终导致细胞死亡。尽管 mtPTP 是许多人类病理的潜在治疗靶点，但其作为药物靶点的潜力目前尚未实现。在这里，我们描述了围绕命中1、5- (3-羟基苯基) -N- (3,4,5-三甲氧基苯基)异恶唑-3-甲酰胺发起的优化工作，发现其对线粒体肿胀具有良好的抑制活性 (EC 50 < 0.39微米) 并显示对线粒体内膜电位没有干扰（罗丹明 123 摄取 EC 50 >100 μ M）。这使得构建一系列皮摩尔 mtPTP 抑制剂成为可能，这些抑制剂也有效地增加了线粒体的钙保留能力。最后，最有效的类似物之一N- (3-氯-2-甲基苯基)-5-(4-氟-3-羟基苯基)异恶唑-3-甲酰胺 ( 60 )的治疗潜力和体内功效是在 VI 型胶原蛋白先天性肌营养不良的生物学相关斑马鱼模型中得到验证。
• Synthesis of a novel and potent small-molecule antagonist of PAC1 receptor for the treatment of neuropathic pain
  作者：Ichiro Takasaki、Haruna Ogashi、Takuya Okada、Ayaka Shimodaira、Daichi Hayakawa、Ai Watanabe、Atsuro Miyata、Takashi Kurihara、Hiroaki Gouda、Naoki Toyooka

  DOI：10.1016/j.ejmech.2019.111902

  日期：2020.1

  identified novel small-molecule antagonists of the PACAP type I (PAC1) receptor using docking-based in silico screening followed by in vitro/vivo pharmacological assays. In the present study, we synthesized 18 novel derivatives based on the structure of PA-9, a recently developed antagonist of the PAC1 receptor, with a view to obtain a panel of compounds with more potent antagonistic and analgesic activities

  我们最近使用基于对接的计算机模拟筛选，然后进行体外/体内药理学鉴定，确定了PACAP I型（PAC1）受体的新型小分子拮抗剂。在本研究中，我们基于PA-9（一种最近开发的PAC1受体拮抗剂）的结构合成了18种新型衍生物，以期获得一组具有更强的拮抗和镇痛活性的化合物。其中，化合物3d显示出改善的拮抗活性。鞘内注射3d抑制垂体腺苷酸环化酶激活多肽（PACAP）和脊髓神经结扎诱导的机械性异常性疼痛。效果比PA-9更有效。口服给药后，化合物3d也显示出抗痛觉过敏作用。因此，
• Synthesis and Microbiological Evaluation of New 2- and 2,3-Diphenoxysubstituted Naphthalene-1,4-diones with 5-Oxopyrrolidine Moieties
  作者：Aušra Voskienė、Birutė Sapijanskaitė、Vytautas Mickevičius、Ilona Jonuškienė、Maryna Stasevych、Olena Komarovska-Porokhnyavets、Rostyslav Musyanovych、Volodymyr Novikov

  DOI：10.3390/molecules171214434

  日期：——

  analysis data. Methyl 1-3-[(3-chloro-1,4-dioxo-1,4-dihydro-2-naphthalenyl)oxy]phenyl}-5-oxo-3-pyrrolidinecarboxylate demonstrated potential antibacterial and antifungal activities as determined by diffusion and serial dilution methods, while N'-[(4-bromophenyl)methylidene]-1-3-[(3-chloro-1,4-dioxo-1,4-dihydro-2-naphthalenyl)oxy]phenyl}-5-oxo-3-pyrrolidinecarbohydrazide and 2-3-[4-(1,2,3-oxadiazol-5

  合成了新的 3-取代 1-(3-羟基苯基)-5-氧代吡咯烷衍生物，其中含有腙、唑、二唑、恶二唑片段，以及 2-苯氧基-和 2,3-二苯氧基-1,4-萘醌衍生物。所有化合物的结构均已通过 NMR、IR、质谱和元素分析数据确认。1-3-[(3-chloro-1,4-dioxo-1,4-dihydro-2-naphthalenyl)oxy]phenyl}-5-oxo-3-pyrrolidinecarboxylate 甲酯显示出潜在的抗菌和抗真菌活性，通过扩散确定和系列稀释方法，而 N'-[(4-溴苯基) 亚甲基]-1-3-[(3-氯-1,4-二氧-1,4-二氢-2-萘基)氧基]苯基}- 5-oxo-3-pyrrolidinecarbohydrazide 和 2-3-[4-(1,2,3-oxadiazol-5-yl)-2-oxo-1-pyrrolidinyl]phenoxy}-3-3-[4-(
• The Reaction of Itaconic Acid with Primary Amines
  作者：Peter L. Paytash、Edward Sparrow、Joseph C. Gathe

  DOI：10.1021/ja01159a520

  日期：1950.3
• Lipp et al., Chemische Berichte, 1958, vol. 91, p. 2239,2241,2245
  作者：Lipp et al.

  DOI：——

  日期：——